Saracatinib（AZD0530）是一种高效的Src家族抑制剂，对c-Src、Lck、c-YES、Lyn、Fyn、Fgr和Blk的IC50范围为2.7至11 nM，显示出对其他酪氨酸激酶的高选择性。

PP2是一种可逆的、ATP竞争性的Src家族激酶抑制剂，对Lck和Fyn的IC50值分别为4 nM和5 nM。

PP1 is a selective inhibitor of Src and Lck/Fyn with IC50 of 5 nM, 6 nM, respectively.

WH-4-023 is an inhibitor of Lck and Src with IC50 of 2 nM, 6 nM, respectively.

CCT196969 is active against melanoma and colorectal cancer cell lines that are mutant for BRAF, but not cancer cells that are wild-type for BRAF and NRAS. CCT196969 induces caspase 3 and PARP cleavage, thus induces apoptosis. CCT196969 does not drive paradoxical pathway activation and inhibit MEK/ERK in BRAF and NRAS mutant melanoma.